Pharmaceutical company Mallinckrodt PLC said its profit soared in the latest quarter as the company’s specialty brand sales continue to benefit from recent acquisitions. But overall sales missed analysts’ lofty expectations, and shares slid 10.4% in midday trading—hitting a six-month low and giving up nearly half of the stock’s gain this year. In March, the […]

Regeneron Inc’s blockbuster eye drug, Eylea, showed no signs of a slowdown as the drugmaker raised the full-year sales forecast for its flagship product above at least four analysts’ expectation. The company’s shares rose to a record of $605.93 in early trading on Tuesday. U.S. sales of Eylea surged 58 percent to $655 million in […]

Irish drugmaker Horizon Pharma (HZNP) fired off a two-pronged maneuver including calling for a special shareholder’s meeting and filing as lawsuit as it continues to take over California-based rival Depomed, Inc. (DEPO).   On Monday the Dublin-based maker of drugs for pain and central nervous system conditions, called a special shareholders meeting seeking the removal […]

CVS Health Corp’s profit beat estimates for the fifth straight quarter, boosted by higher pharmacy claims and strong sales in its business that provides medication and services for serious diseases such as multiple sclerosis and cancer. Revenue from the company’s pharmacy services business rose about 12 percent in the second quarter. The business, which includes […]

Aetna Inc (AET.N) on Tuesday reported a better-than-expected adjusted net profit for the second quarter and said “moderate” medical costs boosted the profitability of its government Medicare and Medicaid plans. The third-largest U.S. health insurer, which is in the process of buying rival Humana Inc (HUM.N), also raised its full-year forecast for adjusted net profit […]

A year ago Shire shares were punished when the U.S. Treasury’s freeze on so-called inversion transactions nixed the company’s sale to AbbVie, a Chicago-based pharma giant looking to save money on taxes by shifting its headquarters abroad. Now, instead of selling to a competitor in the ‘Windy City’, Shire is using its Irish domicile to scoop […]

PHILADELPHIA, Aug. 4, 2015 /PRNewswire/ — The Intellectual Property and Science business of Thomson Reuters, the world’s leading provider of intelligent information for businesses and professionals announced the release of the 2015 CMR Pharmaceutical R&D Factbook, the biopharmaceutical industry’s leading resource of global R&D trends. Despite concerns around declines in R&D, the analysis identifies a surge […]

Tech giant Samsung Electronics Co Ltd said on Monday it will create a 100 billion won ($85.8 million) fund to compensate cancer-stricken workers and their families, and for efforts to prevention such diseases at its chip and display factories. Samsung said in a statement the fund will make payments to workers or families of those […]

Transaction underscores Teva’s “personalized-medicine” approach to treatment optimization across a spectrum of specialty and generics development programs and lifecycle management initiatives Teva gains exclusive rights to Immuneering’s cutting-edge analytics to advance treatments for diseases of the CNS   JERUSALEM & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and privately-held Immuneering Corporation today […]

August 3, 2015By Alex Keown, BioSpace.com Breaking News Staff CARLSBAD, Calif. – Isis Pharmaceuticals, Inc. (ISIS) and AstraZeneca PLC (AZN) inked a deal to develop antisense therapies for cardiovascular, metabolic and renal diseases, the companies jointly announced this morning. This marks a continued trend for Isis to collaborate with a large pharmaceutical company to develop […]